We utilize as well as develop novel state-of-the-art nano-tools and nano-technologies to address above problems. If you want to discuss more along the research lines, please do contact us. This research requires developing skill set in a variety of fields, from physics, optics, chemistry and surface chemistry, cleanroom based nano fabrication, computer programming, modelling & interfacing, ultra-low-noise electronics, optical microscopy, theoretical modeling, molecular biology, microfluidics, DNA and protein engineering, cell biology, single molecule detection using nanopore platform, single molecule force measurements using Laser Optical Tweezers and Atomic Force Microscope as well as molecular visualization using different fluorescence methods.
The high technological complexity of products and services is a feature of the health sector. Therefore, the relationship between the scientific base of universities and institutes and the pharmaceutical industry is a necessary condition for national technological advances in this segment. One strategy already adopted and consolidated by the countries that are at the cutting edge of technological development and that, from the advent of the Innovation Law - Law 10.973/2004 - has been increasingly embraced by Brazilian institutions and Fiocruz is one of the most prominent health institutions from Brazil immersed in the research innovation challenges.
Fiocruz produces, disseminates, and share knowledge and technologies and contributes to the promotion of health and quality of life of the population. Besides the reduction of social inequalities and the national dynamics of innovation, with the defense of the right to health and full citizenship as central values, it uses science and innovation as the basis of socio-economic development and health promotion.
COVID 19, HIV-1, HIV-1 / 2, Chagas’ disease, dengue fever, leishmaniasis, leptospirosis, arboviruses, influenza, and many other diseases are under research at Instituto Oswaldo Cruz. Please take a look at the technological showcase in COVID 19, shared in the links to the research work window.
We want to provide example of science validation of the capability and speed of Micar21 Drug Discovery Platform, which can be viewed and validated through science publications. Early of December no one had accurate data on the effect of the new Covid19 - UK & South Africa mutations on the action of vaccines and on the binding of the virus to ACE2, so Micar21 decided to calculate pro-bono and support science worldwide. On 16.12.2020 - Micar21 starts insilico calculations. On 26.12.2020 - first version of our science publication - with calculation for English mutation COVID19. On 31.12.2020 - second version of our science publication - with calculation for South African mutation COVID19 is included and we published our scientific publication: https://www.biorxiv.org/content/10.1101/2020.12.23.424283v2.article-metrics Dr. Filip Fratev (Micar21) is the sole author of the science publication. In less than 5 months there are already 22 citations (very good result). Our competitors appeared with insilico data for Covid19 Mutations at the end of January 2021 (can be traced through science publications) On 14.02.2021 (sent on 14.02.2021 - published on 23.02.2021) science publication by Oxford, validates Micar21 insilico results with experimental data: https://www.cell.com/cell/pdf/S0092-8674(21)00226-9.pdf Here, through the experimental data, our Micar21 insilico data calculated in December 2020 are proved. Micar21 predicted in silico the stronger N501Y mutant binding to ACE2 (-1.42 kcal/mol) whereas months later experimental data shown a value of (-1.40 kcal/mol), thus, confirming that our in silico results was precise. The aim of Micar21 study and new paper was to provide urgently high quality data about the effect of the UK and South African mutations. However, during the process of revision of the paper many experimental studies became available which was an excellent opportunity for a validation of the in silico approaches employed here and in particular protein-protein FEP. Also, we can compare our results to other data obtained by theoretical approaches which can be viewed and validated through other science publications and showed in our new science publication in Journal of Chemical Information and Modelling - under final review: http://micar21.com/Covid19_UK_SA_mutation.pdf
Big Data Machine Learning Deep Learning Bioinformatics Drug Discovery Forensics 3D Image processsing
- Additive Manufacturing - Electronics - Robots - Bio-additive manufacturing